



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

May 7, 2019: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
  
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**
  
- **Medical Director Update** **6:40 - 6:45**
  
- **Follow-up Items from Previous Meetings** **6:45 - 6:45**
  
- **RetroDUR/ProDUR** **6:45 - 7:00**
  - Introduce: Use of Gabapentin
  - Data presentation: Evaluation of Opioid Prescribing for Chronic Pain
  
- **Clinical Update: Drug Reviews** **7:00-7:35**  
(Public comment prior to Board action)
  - Biosimilar Drug Reviews**
    - Nivestym® (filgrastim-aafi)
    - Udenyca® (pegfilgrastim-cbqv)
  
  - Full New Drug Reviews**  
(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)
    - Abilify Mycite® (aripiprazole with sensor)
    - Cequa® (cyclosporine ophthalmic solution)
    - Inveltys® (loteprednol etabonate ophthalmic suspension)
    - Nocdurna® (desmopressin acetate)
    - Siklos® (hydroxyurea)
    - Tiglutik® (riluzole)
    - Xelpros® (latanoprost ophthalmic solution)
    - Xyosted® (testosterone enanthate)
  
- **New Managed Therapeutic Drug Classes** **7:35 -7:50**  
(Public comment prior to Board action)
  - Continuous Glucose Monitoring Supplies

- Neuropathic Pain/ Fibromyalgia
  
- **Therapeutic Drug Classes – Periodic Review** **7:50 - 8:30**  
(Public comment prior to Board action)
  - Analgesics: Short acting opioids
  - Analgesics: Long acting opioids
  - Epinephrine Auto Injectors
  - Hepatitis B agents
  - Hepatitis C agents
  - Pseudobulbar Affect Agents
  - Topical Corticosteroids (NDR Bryhali Lotion® (halobetasol propionate) included)
  
- **Review of Newly-Developed/Revised Criteria** **8:30 - 8:30**  
(Public comment prior to Board action)
  - None at this time
  
- **General Announcements** **8:30 – 8:30**
  - **Selected FDA Safety Alerts**
    - FDA recently approved revisions to the VIREAD (tenofovir disoproxil fumarate) product labeling to include safety and pregnancy-related outcome information from three published controlled trials in pregnant women with chronic hepatitis B virus infection who were administered VIREAD during their third trimester.  
<http://s2027422842.t.en25.com/e/es?s=2027422842&e=208411&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=ce5ca0323e0f457cba72a3050f17ff99&elqaid=7752&elqat=1>
  
- **Adjourn** **8:30**